Wall Street loves diet drugs and is willing to invest money in pharma companies with drugs in the pipeline. However, recent shifts in funding priorities within the pharmaceutical industry have sparked concerns regarding the disproportionate focus on diet drugs at the expense of other crucial medical advancements. This phenomenon underscores the complex interplay between health, economics, and ethics in the pharmaceutical realm.

The quest for the next blockbuster drug is a high-stakes game in the pharma industry. Two main paths lead to this coveted prize: internal R&D, the detailed but potentially rewarding journey of developing drugs from scratch, and acquisitions, the quicker but pricier route of buying into existing biotechs with promising pipelines. Which is the smarter bet? The answer, like most things in life, is that it depends.